{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigyuyvdqivqqdqllwgllkj2dgsufejxd6f7wfjdat7w3ijp3vz42y",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgem2ob3txn2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreih7iumbiirqbsjzp6phiwovtxbcxcdyshfmwiq4hkk2q6aoeborda"
    },
    "mimeType": "image/png",
    "size": 517385
  },
  "path": "/2026/03/05/vinay-prasad-peter-marks-fda-regulatory-frameworks/?utm_campaign=rss",
  "publishedAt": "2026-03-05T11:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Adam's Biotech Scorecard",
    "Adam's Take",
    "Biotech",
    "biotechnology",
    "FDA",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "With the current leadership of the FDA, the rare-disease community is suffering whiplash. Drugmakers are frustrated. And investors are sitting on their wallets.",
  "title": "STAT+: The extremism of the FDA’s Marks and Prasad has come with costs",
  "updatedAt": "2026-03-05T11:36:53.000Z"
}